Literature DB >> 27150551

Evaluation of antimicrobial efficacy of cetrimide and Glycyrrhiza glabra L. extract against Enterococcus faecalis biofilm grown on dentin discs in comparison with NaOCl.

Hilmi Egemen Güldas1, Ayse Diljin Kececi, Emel Sesli Cetin, Tuba Ozturk, Bulem Üreyen Kaya.   

Abstract

This study aimed to determine the antimicrobial efficacy of NaOCl, cetrimide, and Glycyrrhiza glabra L. extract against Enterococcus faecalis biofilms on dentine discs. Broth microdilution method was used to determine minimal bactericidal concentrations (MBCs) of the agents. A biofilm susceptibility assay was performed using E. faecalis biofilms grown on dentine discs. Minimal bactericidal concentrations (MBCs) of NaOCl (0.5%), cetrimide (0.015%), and G. glabra L. extract (0.25%) were applied for 1, 3, and 5 min, and the mean viable cell counts were recorded and statistically analyzed. There was no significant difference between cetrimide and NaOCl at 1 min (p>0.05). NaOCl was the most effective agent at 3 and 5 min (p<0.05) while G. glabra L. extract was the least (p<0.05). The MBCs of NaOCl, cetrimide, and G. glabra that eliminated the planktonic E. faecalis did not eradicate the biofilms grown on dentin discs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27150551     DOI: 10.4012/dmj.2014-338

Source DB:  PubMed          Journal:  Dent Mater J        ISSN: 0287-4547            Impact factor:   2.102


  2 in total

1.  Spectrum-Effect Relationships Between the Bioactive Ingredient of Syringa oblata Lindl. Leaves and Its Role in Inhibiting the Biofilm Formation of Streptococcus suis.

Authors:  Yan-Yan Liu; Xing-Ru Chen; Ling-Fei Gao; Mo Chen; Wen-Qiang Cui; Wen-Ya Ding; Xue-Ying Chen; Bello-Onaghise God'spower; Yan-Hua Li
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

Review 2.  Potential and Prophylactic Use of Plants Containing Saponin-Type Compounds as Antibiofilm Agents against Respiratory Tract Infections.

Authors:  I Irem Tatli Cankaya; E Inci Somuncuoglu
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-23       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.